Compare BioNTech SE - ADR (BNTX) vs Quantumscape Corp (QS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNTech SE - ADR vs Quantumscape Corp — how do they compare? BioNTech SE - ADR trades at $89.89 (market cap $22.86B), while Quantumscape Corp trades at $6.46 (market cap $3.95B). The key difference: BioNTech SE - ADR is far larger — about 5.8× Quantumscape Corp's market cap, and BioNTech SE - ADR is trading nearer its 52-week high, Quantumscape Corp nearer its low. Which is the better fit depends on your goals.
| BNTX | QS | |
|---|---|---|
Market Cap | $22.86B | $3.95B |
Sector | Health | Consumer Cyclical |
52-Week High | $119.34 | $18.44 |
52-Week Low | $83.89 | $5.96 |
Enterprise Value | $6.53B | $3.11B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BioNTech (BNTX) trades at $90.07, down 1.55% today, amid a bearish technical signal and declining revenue trends. The company reported a net loss of $1.14 billion in 2025, with profitability metrics negative, though it maintains a strong cash position of $16.78 billion. Recent news highlights restructuring efforts, including site closures and a $1 billion share buyback, as it pivots focus to oncology pipeline development following reduced COVID-19 vaccine demand.
The outlook remains challenging with persistent losses and competitive pressures, but analyst consensus is bullish with a $129.67 price target. Key risks include execution of the oncology strategy and revenue volatility. The stock's current valuation reflects uncertainty, offering potential upside if pipeline milestones are met, but investors face significant operational and market headwinds.
QuantumScape (QS) trades at $6.28, down 4.56% today, with a bearish technical outlook and negative profitability metrics. The company reported a net loss of $435.05M in 2025 and relies on financing cash flows to fund operations. Recent news highlights a joint research agreement with Honda, providing a potential catalyst for its solid-state battery technology development.
The outlook remains speculative with high execution risks as QS transitions from R&D to commercialization. Analyst sentiment is cautious with 73% hold ratings. Investment opportunity hinges on successful battery commercialization, but risks include persistent losses, competitive threats, and reliance on external funding.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →About Quantumscape Corp
QuantumScape Corp is engaged in the development of next-generation solid-state lithium-metal batteries for use in electric vehicles. It developed anode-less cell design, which delivers high energy density while lowering material costs and simplifying manufacturing.
Read more on QS →
